natgillin/translations-raw huggingface dataset:
The peptide according to Claim 1, wherein said peptide includes non-peptide bonds. The peptide according to Claim 1 or 2, wherein said peptide is part of a fusion protein. The peptide according to Claim 3, wherein said fusion protein comprises the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu navedeni peptid uključuje nepeptidne veze. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, pri čemu je navedeni peptid dio fuzioniranog proteina, posebice sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
A process for preparing cross-linked polymers or salts thereof comprising a repeating unit of Formula (I), and/or Formula (II), wherein n is an integer and X- is an inorganic or organic pharmaceutically acceptable anion, such as halide, phosphate, phosphite, carbonate, bicarbonate, sulphate, bisulfate, hydroxide, nitrate, persulfate, sulfite, sulphide, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, colate; 
(ll) naznačen time da n je cijeli broj i X je anorganski ili organski farmaceutski prihvatljiv anion, kao halid, fosfat, fosfit, karbonat, bikarbonat, sulfat, bisulfat, hidroksid, nitrat, persulfat, sulfit, sulfid, acetat, askorbat, benzoat, citrat, dihidrogen citrat, hidrogen citrat, oksalat, sukcinat, tartrat, taurokolat, glikokolat, ili kolat; koji postupak sadrži: reakciju alilamina u prisutnosti kiseline sa sredstvom za umrežavanje prema formuli (TV)
Thus, contrary to conventional non-photo polymerisable dental filling materials, the dental filling materials of some embodiments of the invention may be prepared, stored and shipped as a one-component system. 
Stoga se nasuprot konvencionalnim ne-foto dentalnim materijalima za punjenje koji polimeriziraju, mogu pripraviti dentalni materijali za punjenje iz nekih cjelina, čuvati 1 slati kao jednokomponentni sustav.
is hydrogen; is a group represented by the formula —NR9R10; 
R* je skupina prikazana formulom -NR*R'"
Table 2 lists some agents useful in treating AIDS and HIV infection which are suitable for this method. 
U Tablici 2 navedena su neka sredstva korisna u liječenju SIDA-e 1 HIV infekcije koja su pogodna za ovaj postupak.
The polypeptide or composition for use of claim 10, wherein said subject at risk of CDAD is over 65 years. 
Polipeptid 1li sastav za uporabu iz patentnog zahtjeva 10, pri čemu je navedeni subjekt s rizikom od CDAD stariji od 65 godina.
A compound having the structure: or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof. 
Spoj formule (I): ili njegov stereoizomer, tautomer, ili farmaceutski prihvatljiva sol, pri čemu:
said at least one hole (73) being provided in correspondence to said inclined portion. 
pri čemu je navedena najmanje jedna rupa (73) osigurana u skladu sa navedenim nagnutim dijelom.
More details about the connection of the outputs of the receiver, to the electronic controls of the boat, are provided in Figure 4. 
Više pojedinosti o priključivanju izlaza prijemnika na elektroničke kontrole plovila je prikazano na Slici 4.
Use according to claim 9 wherein the composition of any of claims 1-6 or 8 is used as surface cleaner for sand, rock formations, shorelines, machinery, tanks, tankers or oil drilling equipment. 
Sredstvo za čišćenje površina, koje pospješuje uklanjanje nafte s pijeska, kamenih formacija, obala, mehanizacije, spremnika, tankera ili opreme za bušenje nafte, koje se sastoji od C6-C14 alkillpoliglukozida (APG);
The formulation of claim 1, wherein the formulation has a pH of 2.5 to 4.5. 
Formulacija iz patentnog zahtjeva 1, pri čemu formulacija ima pH od 2.5 do 4.5.
The method according to claim 2, wherein the recombinant staphylococcal clumping factor A (ClfA) amino acid residues Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 are substituted with either Ala or Ser. 
Rekombinantni stafilokokni faktor grudanja A (CIfA) za uporabu u liječenju ili prevenciji stafilokoknih infekcija prema bilo kojem od prethodnih zahtjeva gdje CIfA ili njegov fragment obuhvaća aminokiselinske ostatke Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 i/ili Val527 koji su supstituirani s Ala ili Ser.
Consistent control of plasma glucose levels in diabetes patients may offset the development of diabetic complications and beta cell failure seen in advanced disease. 
Redovna kontrola nivoa glukoze u plazmi kod pacijenata sa dijabetesom može odgoditi razvoj dijabetečnih komplikacija i otkazivanje beta stanica koje se može vidjeti kod uznapredovale bolesti.
The composition according to Embodiment 78, wherein the composition is in the form of granules. 
Smjesa prema zahtjevu 1, gdje je smjesa u obliku granula.
The method of anyone of claims 11 or 12, wherein the immune response is protective immune response in a patient against CMV infection. 
Kompozicija za uporabu prema patentnom zahtjevu 4, naznačena time što je imunološki odgovor zaštitni imunološki odgovor kod pacijenta protiv CMV infekcije.
This blocking effect will lead to the pressure raising at the upstream-side of the sealing member which in turn will lead to the sealing member being pressed even stronger against the sealing surface and thus to a sealing engagement which is the stronger the higher the pressure at the sealing engagement. 
Djelovanje ovog blokiranja će dovesti do porasta tlaka na strani dovoda od elementa za brtvljenje, što će zatim redom dovesti do toga da se element za brtvljenje još jače pritisne na površinu za brtvljenje i na taj način dovesti do zahvaćanja brtve koje je tim jače, što je viši tlak prilikom brtvljenja.
The method of 37, wherein the subject has a disorder selected from the group consisting of multiple sclerosis, systemic lupus erythematosus and diabetes. 
Antitijelo ili antigen-vežući fragment istog iz Zahtjeva 1, naznačeno time, što se koristi za liječenje poremećaja odabranih iz grupe koja se sastoji od multiple skleroze, sistemskog lupusa eritematozusa i dijabetesa.
The method as claimed in claim 3, wherein said alkaline medium is selected from the group consisting of sodium hydroxide (NaOH or caustic), ammonia or amine compound, and mixture thereof. 
Metoda temeljem zahtjeva 3, naznačena time što je navedeni lužnati medij izabran iz skupine koju čine spoj natrij hidroksida (NaOH ili kaustična soda), amonijaka ili amina, ili njihova mješavina.
The DNA polymerase chimera according to claim 3, wherein the amino acid sequence of (c) is SEQ ID NO: 3 bound by its C-terminal end to SEQ ID NO: 4. 
DNK polimeraza himera prema zahtjevu 3, gdje je lanac amino kiseline od O SEQ ID NO: 3 povezan svojim C-krajem za SEQ ID NO: 4.
The use according to Claim 9, wherein the spectral separation filters comprise passbands that are red-shifted compared to corresponding wavelength bands in at least one of the spectrally separated images to be viewed. 
Uporaba prema zahtjevu 11, naznačena time što filtri za razdvajanje spektra sadrže prolazne pojaseve koji su crveno pomaknuti u usporedbi s odgovarajućim pojasevima valnih duljina u barem jednoj od spektralno odijeljenih slika za pregledavanje.
Ra is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl; 
Ra je vodik, alkil ili supstituirani alkil, alkenil ili supstituirani alkenil, alkinil ili supstituirani alkinil, cikloalkil ili supstituirani cikloalkil, cikloalkenil ili supstituirani cikloalkenil, heterocikl ili supstituirani heterocikl, ili aril ili supstituirani aril;
An antibody according to claim 1 or 6, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:40. 
Protutijelo u skladu s patentnim zahtjevom I ili 6, gdje varijabilno područje lakog lanca sadrži aminokiselinski slijed iznijet u SEQ ID NO: 40.
It is also disclosed that the soaked ligno-cellulosic biomass stream before separation step e) may be substantially void of the free liquid. 
Proces iz patentnog zahtjeva 7, gdje struja natopljene ligno-celulozne biomase prije koraka odvajanja e) je suštinski bez slobodne tekućine.
The method according to any one of the preceding claims, CHARACTERIZED IN THAT a further step c) is provided following the combination of steps a) and b), wherein a further amount of concentrated mineral acid with a water content of less than 50 weight% is added to the ammonium nitrate-based particles. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se daljnji korak c) izvodi nakon kombinacije koraka a) 1 b), pri čemu se česticama na bazi amonijeva nitrata dodaje dodatna količina koncentrirane mineralne kiseline s udjelom vode manjim od 50 % težinskih udjela.
The process according to claim 1 or 2, wherein the B-(substituted-amino)thiolcarbonic acid ester comprises a thiolcarbonic acid ester portion R14-S-C(O)-, wherein R14 is alkyl or aryl. 
Postupak prema patentnom zahtjevu 1 ili 2, gdje B-(supstituirani-amino)tiolkarbonski kiselinski ester obuhvaća udio estera tiol karbonske kiseline R14-S-C(O)-, pri čemu je R14 alkil ili aril.
In solution fructose, for example, can exist mostly in a 6-membered pyranose form and/or its 5-membered furanose form. (See FIG. 1). 
U otopini fruktoza, na primjer, može postojati većinom u 6-članom piranoznom obliku i/ili svojem 5-članom furanoznom obliku (v. sliku 1).
A device according to any of the preceding claims, wherein the device further comprises adjustment means (23) connected to at least one of said enclosing members (10a,10b) in order to adjust the relative position of the enclosing members in closure. 
Naprava u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što naprava dodatno sadrži podešavač (23), povezan s najmanje jednim od navedenih elemenata za obuhvaćanje (10a, 10b) radi podešavanja relativnog položaja elemenata za obuhvaćanje kod zatvaranja.
The method according to claim 11, wherein said malignant cells are cells from a tumor selected from the group consisting of a hematological tumor and a solid tumor. 
Uporaba ili nanočestice HfO, ili agregati nanočestica HfO> za uporabu prema zahtjevu 13, gdje su spomenute maligne stanice stanice od tumora odabranog iz skupine koju čine hematološki tumor i solidni tumor.
is a hydrogen atom or COOH; R2 is a hydrogen atom, a C1-6 alkyl group optionally substituted by a C1-6 alkoxy group, a C3-10 cycloalkyl group, or COOH; and either one of R1 and R2 is COOH, and each of R3, R4, R5, and R6 is a hydrogen atom, 
je vodikov atom ili COOH; R2 je vodikov atom, C1-6 alkilna skupina opcionalno supstituirana s C1-6 alkoksi skupinom, C3-10 cikloalkilna skupina, ili COOH; i bilo R1 ili R2 jest COOH, i svaki od R3, R4, R5 i R6 je vodikov atom, ili njegova farmakološki prihvatljiva sol.
The method according to claim 1, wherein following addition of 2-((1-methylpropyl)amino)ethanol to the suspension, the suspension is introduced in a unit equipped with a conductivity-based regulation device. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da se, nakon dodavanja navedenog 2-((1-metilpropiljaminojetanola u navedenu suspenziju, suspenzija dodaje u jedinicu opremljenu napravom za regulaciju na temelju vodljivosti.
These objects are surprisingly solved by a method for the preparation of a pharmaceutical composition containing venlafaxine or a pharmaceutically acceptable salt thereof comprising the steps of 
Ovi ciljevi iznenađujuće su riješeni postupkom dobivanja farmaceutskog pripravka koji sadrži venlafaksin ili njegovu farmaceutski prihvatljivu sol, koji se sastoji u koracima
The use according to claim 16 or 17, wherein the disease or condition is neuropathic pain or pseudobulbar affect. 
Uporaba u skladu s patentnim zahtjevom 19, pri čemu je bolest ili stanje neuropatska bol ili pseudobulbarni afekt.
Ethyl acetate was added to the resultant solution. 
Rezultirajućoj otopini dodan je etil acetat.
The compounds may be administered either orally or preferably parenterally, alone or in combination with other anti-neoplastic agents or with other therapeutic agents, such as steroids, to a mammal, preferably a human, suffering from neoplasm and in need of treatment. 
Spojevi se mogu primjenjivati ili oralno ili poželjno parenteralno, sami ili u kombinaciji s drugim anti-neoplastičnim tvarima ili s drugim terapeutskim tvarima, kao što su steroidi, na sisavca, poželjno čovjeka, koji pati od neoplazme i potreban mu je tretman.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for the use according to claim 22, wherein the disease is multiple myeloma. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 17, naznačeno time da je bolest multipli mijelom.
According to an advantageous characteristic, the data processor unit of the surveillance tool is adapted to calculate a real consumption of the machine from the stored rows of data. 
Elektronički sustav u skladu s jednim od prethodnih zahtjeva, naznačen time da je jedinica za obradu podataka (21) kontrolnog uređaja (2) prilagođena za izračunavanje stvarne potrošnje uređaja (1) iz pohranjenih redova podataka.
Process according to claim 1, wherein the alkali in step (a) is chosen from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide and mixtures thereof, the weight ratio of alkali to crude or refined oil is approximately 0.15:1, and the weight ratio of water to crude or refined oil is between 0.5:1 and 2:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se alkalija u koraku (a) bira iz skupine koju čine natrijev hidroksid, kalijev hidroksid, litijev hidroksid, magnezijev hidroksid i njihove smjese, težinski omjer između alkalije 1 sirovog ili rafiniranog ulja je približno 0,15:1, a težinski omjer između vode 1 sirovog ili rafiniranog ulja je između 0,5:1 12:1.
represents (i) a cyclohexyl group substituted by 1 to 2 substituents independently selected from hydroxy or amino, or (ii) a heterocyclic group having from 6 atoms, said heterocyclic group being substituted by a hydroxy or an amino; or a pharmaceutically acceptable salt thereof. 
R* predstavlja (i) cikloheksilnu skupinu, supstituiranu s 1 do 2 supstituenta, koje se neovisno bira između hidroksi skupine ili amino skupine, ili (ii) heterocikličku skupinu s 6 atoma, gdje je navedena heterociklička skupina supstituirana s hidroksi skupinom ili amino skupinom.
r is 0 or 1 and when r is 0 then a direct bond is intended; 
r je 0 ili 1, te kada r je 0 tada je namjeravana direktna veza;
is selected from the group consisting of methyl, isopropyl, cyclopentyl, cyclopropyl, 2-furanyl, trifluoromethyl, methoxymethyl, aminomethyl, dimethylaminomethyl, dimethylamino-1-ethyl, 1-dimethylamino-ethyl, and 2-dimethylamino-ethyl, wherein R2 is optionally substituted with deuterium; 
R? je odabran iz skupine koja sadrži metil, izopropil, ciklopentil, ciklopropil, 2-furanil, trifluorometil, metoksimetil, aminometil, dimetilaminometil, dimetilamino-1-etil, 1-dimetilamino-etil, i 2-dimelilamino-etil, pri čemu R? je proizvoljno supstituiran sa deuterijem;
positioning the sample near the plume, such that the target material particles are deposited onto the surface of the sample. Description of the Related Art 
- < postavljanje uzorka blizu prašine, tako da se čestice ciljnog materijala nanose na površinu uzorka;
The electromagnetic relay assembly of claim 3 wherein the contact-spring assemblies comprise second spring means, the second spring means for enhancing damped contact vibration intermediate the contacts when switching from the open position to the closed position. 
Elektromagnetski relejni sklop u skladu s patentnim zahtjevom 3, naznačen time što krakovi opruge sadrže drugu oprugu, gdje druga opruga pojačava prigušeno vibriranje kontakata između kontakata prilikom preklapanja iz otvorenog položaja u zatvoreni položaj.
The manufacturing process comprises process steps of: curving the inside of the transparent stone (1), forming a space therein and providing an outer shell (1 . 
- rezbarenje unutarnje strane navedenog transparentnog kamena (1), formirajući prostor i ostavljajući vanjsku ljusku (1.1),
fraction A is conveyed to a chlorination reactor and fraction B to an oxychlorination reactor, in which reactors most of the ethylene present in fractions A and B is converted to 1,2-dichloroethane; the 1,2-dichloroethane obtained is separated from the streams of products derived from the chlorination and oxychlorination reactors. 
C) frakcija A je prenesena u reaktor za klorinaciju, a frakcija B u reaktor za oksiklorinaciju, te se u tim reaktorima većina etilena koja se nalazi u frakcijama A i B, pretvara u 1,2-dikloroetan; d) dobiveni 1,2-dikloroctan se odvaja od tokova produkata dobivenih u reaktorima za klorinaciju i oksiklorinaciju.
a nucleic acid complementary to a nucleic acid as defined in a), b) or c); 
nukleinska kiselina komplementarna s nikleinskom kiselinom definiranom pod a),
The method as defined in claim 3, wherein the nuclear receptor is an estrogen receptor, androgen receptor, progesterone receptor, thyroid hormone receptor or retinoic acid receptor. 
Upotreba u skladu s patentnim zahtjevom 3, naznačena time što je nuklearni hormonski receptor receptor estrogena, receptor androgena, receptor progesterona, receptor tireoidnog hormona, receptor glukokortikoidnog hormona ili receptor retinske kiseline.
ID NO: 8; the glycan comprising a terminal GlcNAc-moiety is according to formula (1) or (2): wherein: 
ID NO: 8; glikan koji sadrži terminalni ostatak GleNAc ima formulu (1) ili (2):
then converting the compound 15 to the compound of Formula I. 
(o) zatim konverziju spoja 15 do spoja formule I.
A method of encoding a video, the method comprising: 
Naprava za dekodiranje videa, gdje naprava sadrži:
Lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and the active ingredient were screened into a blender and blended for 15 minutes at 30 rpm. 
Bezvodna laktoza, mikrokristalna celuloza, kroskarameloza natrij i aktivni sastojak se prosiju u miješalicu i miješaju 15 minuta pri 30 okr/min.
The apparatus of any one of claims 1 to 6, wherein the elastic rings (20) are configured to permit the inflatable containers (18) to be removed from the tubes (16) by falling off, or by manually shaking them off, when the containers (18) have reached the desired size. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da su elastični prstenovi (20) konfigurirani tako da omogućuju da se spremnici na napuhavanje (18) uklanjaju iz cijevi (16) tako što otpadnu, 1li ih se ručno protrese, kada su spremnici (18) dostigli željenu veličinu.
A multipurpose solution according to any of claims 1 to 8, wherein the cleaning agent and alkaline component of the buffering system is a mixture of monobasic sodium phosphate, NaH2PO4 and dibasic sodium phosphate, Na2HPO4. 
Višenamjenska otopina u skladu sa zahtjevima od 1 do 8, čije je sredstvo za čišćenje i alkalna komponenta sustava za puferiranje smjesa jednobaznog natrijeva fosfata (NaH2PO4) i dvobaznog natrijeva fosfata (Na2HPO4).
A preferred embodiment relates to the compounds of the invention having formula IA. 
Preferirani oblik koji se odnosi na spojeve izuma formule IA.
An oral pharmaceutical tablet according to claim 8, wherein the binder is present in an amount from 0.1% to 10%, preferably from 0.5% to 9%, and more preferably from 1% to 7.5% by weight of the total weight of the tablet. 
Oralna farmaceutska tableta u skladu s patentnim zahtjevom 8, naznačena time što vezivo čini, količinski, od 0,1% do 10%, po mogućnosti od 0,5% do 9%, a poželjnije od 1% do 7,5%, težinski, od ukupne težine tablete.
combining a compound of claim 1 selected from the group consisting of: and with a pharmaceutical excipient to form a pharmaceutical composition; 
(a) kombiniranje spoja u skladu s patentnim zahtjevom 1, koji se odabire iz skupine koju čine: po
In a further aspect, the teaching relates to a T cell receptor which binds to a peptide of the teaching, optionally in a complex with an MHC molecule, and preferably is reactive with said peptide, or a polypeptide chain of said T cell receptor. 
T stanični receptor koji se specifično veže za peptid sukladno patentnom zahtjevu 1 ili 2, izborno u kompleksu s MHC molekulom, naznačen time, što je T stanični receptor odabran iz skupine sastavljene od:
A kit for metagenomic identification of DNA present in a food sample, comprising a set of primers for the metagenomic amplification of a metagenomic target sequence in the myostatin gene, said metagenomic target sequence being selected to allow for: i) co- amplification of the metagenomic target DNA sequence from a plurality of species using a set of conserved, common primers of the kit comprising primers comprising or consisting of the sequence of SEQ ID NO. 
Pribor za metagenomsku identifikaciju DNK prisutne u uzorku hrane, sadržeći set početnica za metagenomsku amplifikaciju metagenomske ciljne sekvence u miostatin genu, navedena metagenomska ciljna sekvenca bivajući odabrana zbog omogućavanja: 1) koamplifikacije metagenomske ciljne DNK sekvence od pluraliteta vrsti koristeći set očuvanih, uobičajenih početnica iz pribora sadržeći početnice koje sadrže ili se sastoje od sekvence SEQ ID NO.
has an anti-tumor activity in vivo; and/or 
(a) posjeduje protutumorsko djelovanje in vivo; i/ili
The Jak1 and/or Jak2 inhibitor for use according to claim 1, wherein the Jak1 and/or Jak2 inhibitor is in a composition suitable for intravenous, intramuscular, intra-peritoneal, intradermal, subcutaneous, oral, nasal, transdermal, topical, transmucosal, or rectal administration. 
Jak1 i/ili Jak2 inhibitor za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je Jak1 i/ili Jak2 inhibitor u pripravku prikladnom za intravensku, intramuskularnu, intra-peritonealnu, intradermalnu potkožnu, oralnu, nazalnu, transdermalnu, topikalnu, transmukoznu, ili rektalnu primjenu.
A packaging according to claim 14, further comprising a security member adapted to retain the retaining member in the retaining position. 
Pakiranje u skladu s patentnim zahtjevom 14, naznačeno time, što nadalje sadržava zaštitni član koji je prilagođen da drži član za držanje u položaju za držanje.
an allocated input area (210) located above said drum for allowing a returnable item received in the input area to be placed on a part of the circumferential surface of said drum facing towards the input area, when the drum is in a rotational position with the mouth opening of the radially extending recess not facing the input area, and 
- namjensko ulazno područje (210) za primitak povratnih artikala koji se trebaju postaviti na gornji obodni dio bubnja kad je bubanj u navedenom prvom rotacijskom položaju, pri čemu je ulazno područje smještena iznad navedenog bubnja, pogon elementa je prilagođen da pozicionira element u uvučenom položaju kad se bubanj nalazi u drugom rotacijskom položaju s udubljenjem u bubnju okrenutim prema gore prema ulaznom području, i
Har1 is optionally substituted by R6111 and/or R6112, and is a monocyolic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which is halogen, or 1-4C-alkyl, 
Harl je izborno supstituiran s R6111 i/ili R6112 i monociklički je ili kondenzirani biciklički 5- do 10-eročlani nezasićeni heteroaromatski prsten, koji sadrži jedan do tri heteroatoma, od kojih se svakog bira iz skupine koju čine dušik, kisik i sumpor, gdje R6111 je halogen ili 1-4C-alkal, R6112 je 1-4C-alkil, 1